

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR**

### **RESIGNATION OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) has received the written resignations tendered by Mr. Eddy HUANG (“**Mr. Huang**”), a non-executive Director, and Mr. ZHAO Dayao (“**Mr. Zhao**”), an independent non-executive Director, with effect from 20 September 2022. Mr. Huang resigned from his positions as a non-executive Director and a member of the nomination committee of the Board (the “**Nomination Committee**”) due to his other business commitments. Mr. Zhao resigned from his positions as an independent non-executive Director, the chairman of the Nomination Committee and a member of the audit committee of the Board (the “**Audit Committee**”) due to his other business commitments.

Each of Mr. Huang and Mr. Zhao confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude to Mr. Huang and Mr. Zhao for their valuable efforts and contributions to the Company during their tenure of office.

### **NON-COMPLIANCE WITH LISTING RULES**

After the resignation of Mr. Huang and Mr. Zhao, the composition of the Board committees of the Company failed to meet the following requirements under:

- (1) (a) Rule 3.21 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) that the Audit Committee shall comprise a minimum of three members with a majority of independent non-executive Directors and (b) the terms of reference of the Audit Committee;

- (2) (a) Rule 3.27A of the Listing Rules that the Nomination Committee shall be chaired by the chairman of the Board or an independent non-executive Director and the members shall comprise a majority of independent non-executive Directors and (b) the terms of reference of the Nomination Committee.

As such, the Board will make its best endeavours to identify appropriate candidates to re-comply with the relevant requirements under the Listing Rules and the terms of reference of the Audit Committee and the terms of reference of the Nomination Committee within three months from the date of resignation of Mr. Huang and Mr. Zhao as required by the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate.

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfa**  
*Chairman*

Hubei, the PRC

30 September 2022

*As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*